• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

350
64
46
44
20

COUNTRY

43
11
5
5
4

PRICE

176
451
667
1,244

PUBLISHED

34
158
388
1,244

PRODUCT TYPE

1,212
17
11
4

Central Nervous System

In 2012 major changes might revolutionize the treatment of multiple sclerosis, as Gilenya, the first novel drug in five years, will be joined by three new products: BG-12, Aubagio, and Lemtrada. Recent exciting developments in drug discovery might also enhance the hopes of those fighting against Alzheimer.

Great commercial and scientific opportunities are to be found in similar battles against a range of diseases and neurodegenerative disorders, e.g. Parkinson’s disease, schizophrenia, migraine, insomnia, epilepsy, etc.

A wide selection of industry reports, scientific journals and academic textbooks in this section allow readers to explore every conceivable facet of this industry, such as market trends, industry forecasts, new drugs in development, the latest research & development, patent applications, and licensing strategies.

Key players featured in our publications include Biogen Idec, Sanofi, Genzyme, and many more. Show Less
Read more

PRODUCT TITLE

AIDS Associated Dementia Global Clinical Trials Review, H1, 2014

AIDS Associated Dementia Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “AIDS Associated Dementia Global Clinical Trials Review, H1, 2014" provides data on the AIDS Associated...

May 2014
FROM

Autism Global Clinical Trials Review, H1, 2014

Autism Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, “Autism Global Clinical Trials Review, H1, 2014" provides data on the Autism clinical trial scenario. This report...

May 2014
FROM

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2014’, provides an overview of the...

May 2014
FROM

Ischemic Cerebral Stroke - Pipeline Review, H1 2014

Ischemic Cerebral Stroke - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Ischemic Cerebral Stroke - Pipeline Review, H1 2014’, provides an overview of the Ischemic Cerebral Stroke’s therapeutic...

May 2014
FROM

Moderate Pain - Pipeline Review, H1 2014

Moderate Pain - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Moderate Pain - Pipeline Review, H1 2014’, provides an overview of the Moderate Pain’s therapeutic pipeline. This report...

May 2014
FROM

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2014

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2014 Summary Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H1 2014’, provides an overview of the...

May 2014
FROM

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market...

May 2014
FROM

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

PharmaPoint: Major Depressive Disorder - Current and Future Players

PharmaPoint: Major Depressive Disorder - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Major Depressive Disorder - Current and Future Players”. The report...

May 2014
FROM

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded...

May 2014
FROM

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a...

May 2014
FROM

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is...

May 2014
FROM
Loading Indicator

Our Clients

Our clients' logos